Research programme: transforming growth factor beta-1 receptor antagonists - Biogen Idec

Drug Profile

Research programme: transforming growth factor beta-1 receptor antagonists - Biogen Idec

Alternative Names: SM-16

Latest Information Update: 24 Feb 2011

Price : $50

At a glance

  • Originator Biogen Idec
  • Class Small molecules
  • Mechanism of Action Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Feb 2011 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 16 Apr 2008 Preclinical pharmacodynamics data presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top